Axsome Therapeutics (AXSM) announced the FDA has approved AUVELITY for the treatment of agitation associated with dementia due to Alzheimer's disease. The FDA approval of AUVELITY is supported by a clinical program which included the Phase 3 ADVANCE-1 and ACCORD-2 studies.
AUVELITY is a first-in-class treatment for Alzheimer's disease agitation which targets the N-methyl D-aspartate and sigma-1 receptors. It was developed with FDA Breakthrough Therapy designation and evaluated by the FDA under Priority Review. AUVELITY is also FDA-approved for the treatment of major depressive disorder in adults.
At last close on NasdaqGM, Axsome shares were trading at $207.75, up 12.94%.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.